The US District Court for the Northern District of California reaffirms the importance of market definition in antitrust merger analysis (Golden Gate Pharmacy / Pfizer)

On April 16, 2010, Judge Maxine M. Chesney of the U.S. District Court for the Northern District of California dismissed a complaint raising a private antitrust challenge to the merger of Pfizer, Inc. and Wyeth Pharmaceuticals, because she concluded that the complaint failed sufficiently to allege the existence of a cognizable relevant product market. See Golden Gate Pharmacy Servs., Inc. v. Pfizer, Inc., No. C-09-3854, 2010 WL 1541257 (N.D. Cal. Apr. 16, 2010). In dismissing the complaint, which plaintiffs already had amended twice, Judge Chesney applied established case law that emphasizes the importance of properly defining a relevant market when determining whether a merger violates the antitrust laws. Judge Chesney’s decision is noteworthy coming just four days before the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Skadden, Arps, Slate, Meagher & Flom (Washington DC)
  • Skadden, Arps, Slate, Meagher & Flom (New York)

Quotation

Gary A. MacDonald, Matthew P. Hendrickson, The US District Court for the Northern District of California reaffirms the importance of market definition in antitrust merger analysis (Golden Gate Pharmacy / Pfizer), 16 April 2010, e-Competitions April 2010, Art. N° 45422

Visites 359

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues